© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 24, 1879-1885,
December 19, 2001
© 2001 Oxford University Press
REPORT |
Nitric Oxide-Mediated Regulation of Chemosensitivity in Cancer Cells
Affiliations of authors: N. E. Matthews, L. R. Maxwell, C. H. Graham (Department of Anatomy and Cell Biology), M. A. Adams, T. E. Gofton (Department of Pharmacology and Toxicology), Queen's University, Kingston, ON, Canada.
Correspondence to: Charles H. Graham, Ph.D., Department of Anatomy and Cell Biology, Botterell Hall, Rm. 859, Queen's University, Kingston, ON, Canada K7L 3N6 (e-mail: grahamc{at}post.queensu.ca) or Michael A. Adams, Ph.D., Department of Pharmacology and Toxicology, Botterell Hall, Queen's University, Kingston, ON, Canada K7L 3N6 (e-mail: adams{at}post.queensu.ca).
Background: Hypoxia in tumors is associated with malignant progression, metastatic spread, and increased resistance to radiotherapy and chemotherapy. Molecular O2 is required for the cellular production of nitric oxide (NO) by the enzyme NO synthase (NOS), and NO may block components of the adaptive response to hypoxia. Hence, we hypothesized that hypoxia increases drug resistance in tumor cells by inhibiting endogenous NO production. Methods: Human breast carcinoma (MDA-MB-231) and mouse melanoma (B16F10) cells were pre-exposed to 20% O2, 5% O2, or 1% O2, incubated with a pharmacologic inhibitor of endogenous NO production, and then treated with chemotherapeutic agents. Resistance was assessed by colony-formation assays, and western blot analysis was used to measure NOS protein levels. All P values were two-sided. Results: Incubation of MDA-MB-231 tumor cells in 1% O2 maximally increased their resistance to doxorubicin and 5-fluorouracil by 8.5-fold (P = .002) and 2.3-fold (P = .002), respectively, compared with incubation in 20% O2. B16F10 mouse melanoma cells preincubated in 1% O2 (versus 20% O2) for 12 hours exhibited a twofold increase in resistance to doxorubicin (P<.001). The rapid acquisition of drug resistance after exposure to 1% O2 could be mimicked by incubating the MDA-MB-231 cells for 12 hours with the NOS inhibitor NG-monomethyl-Larginine (fivefold increase; P<.001). Conversely, replacement of NO activity by use of the NO-mimetic glyceryl trinitrate (GTN) and diethylenetriamine NO adduct produced statistically significant attenuations in the development of resistance of 59% (P<.001) and 40% (P<.001), respectively, in MDA-MB-231 cells. Treatment of B16F10 cells with GTN produced a 58% reduction in resistance (P<.001). MDA-MB-231 cells expressed all three isoforms of the NOS enzyme at levels that were not altered by exposure to hypoxia. Conclusions: NO mediates chemosensitivity in tumor cells, and hypoxia-induced drug resistance appears to result, in part, from downstream suppression of endogenous NO production. These results raise the possibility that administration of small doses of NO mimetics could be used as an adjuvant in chemotherapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-Y. Choi, W. E. Barlow, K. S. Albain, C.-C. Hong, J. G. Blanco, R. B. Livingston, W. Davis, J. M. Rae, I-T. Yeh, L. F. Hutchins, et al. Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial Clin. Cancer Res., August 15, 2009; 15(16): 5258 - 5266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sullivan and C. H. Graham Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1 Mol. Cancer Ther., June 1, 2009; 8(6): 1702 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sullivan, G. C. Pare, L. J. Frederiksen, G. L. Semenza, and C. H. Graham Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity Mol. Cancer Ther., July 1, 2008; 7(7): 1961 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Siemens, N. Hu, A. K. Sheikhi, E. Chung, L. J. Frederiksen, H. Pross, and C. H. Graham Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide Cancer Res., June 15, 2008; 68(12): 4746 - 4753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Frederiksen, R. Sullivan, L. R. Maxwell, S. K. Macdonald-Goodfellow, M. A. Adams, B. M. Bennett, D. R. Siemens, and C. H. Graham Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling Clin. Cancer Res., April 1, 2007; 13(7): 2199 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Baser, V. R. Shannon, G. A. Eapen, C. A. Jimenez, A. Onn, E Lin, and R. C. Morice Smoking Cessation After Diagnosis of Lung Cancer Is Associated With a Beneficial Effect on Performance Status Chest, December 1, 2006; 130(6): 1784 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yasuda, K. Nakayama, M. Watanabe, S. Suzuki, H. Fuji, S. Okinaga, A. Kanda, K. Zayasu, T. Sasaki, M. Asada, et al. Nitroglycerin Treatment May Enhance Chemosensitivity to Docetaxel and Carboplatin in Patients with Lung Adenocarcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6748 - 6757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhou, R. Kohl, B. Herr, R. Frank, and B. Brune Calpain Mediates a von Hippel-Lindau Protein-independent Destruction of Hypoxia-inducible Factor-1{alpha} Mol. Biol. Cell, April 1, 2006; 17(4): 1549 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yasuda, M. Yamaya, K. Nakayama, T. Sasaki, S. Ebihara, A. Kanda, M. Asada, D. Inoue, T. Suzuki, T. Okazaki, et al. Randomized Phase II Trial Comparing Nitroglycerin Plus Vinorelbine and Cisplatin With Vinorelbine and Cisplatin Alone in Previously Untreated Stage IIIB/IV Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2006; 24(4): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Okamoto, T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. Yanaihara, K. Yamada, O. Takikawa, et al. Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells Clin. Cancer Res., August 15, 2005; 11(16): 6030 - 6039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Mariadason, D. Arango, Q. Shi, A. J. Wilson, G. A. Corner, C. Nicholas, M. J. Aranes, M. Lesser, E. L. Schwartz, and L. H. Augenlicht Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin Cancer Res., December 15, 2003; 63(24): 8791 - 8812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-M. Postovit, M. A. Adams, G. E. Lash, J. P. Heaton, and C. H. Graham Oxygen-mediated Regulation of Tumor Cell Invasiveness. INVOLVEMENT OF A NITRIC OXIDE SIGNALING PATHWAY J. Biol. Chem., September 13, 2002; 277(38): 35730 - 35737. [Abstract] [Full Text] [PDF]
|
|